Overview

Autoimmune Basis for Postural Tachycardia Syndrome

Status:
Enrolling by invitation
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if some people with postural tachycardia syndrome (POTS) have higher levels of immune proteins (autoantibodies) directed against receptors of the autonomic nervous system, and if these autoantibodies make a difference in their POTS symptoms. The investigators also want to see if the levels of these autoantibodies stay the same over time.
Phase:
N/A
Details
Lead Sponsor:
Vanderbilt University
Vanderbilt University Medical Center
Collaborator:
University of Oklahoma
Treatments:
Autoantibodies
Isoproterenol
Oxymetazoline
Phenylephrine